The announcement announced today highlights the potential breadth of the KidneyIntelX platform, opening up new routes to expand data inputs and test utility, and create opportunities alongside pharmacological therapy as a companion diagnostic. The first agreement with the University of Michigan adds an additional 800 chronic kidney disease (CKD) patients (adding to Mount Sinai’s 1,500 patients and the University of Groningen’s 3,500 patients) to analysis the performance of KidneyI
30 Jun 2020
Two key agreements seeking to expand the utility of KidneyIntelX
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Two key agreements seeking to expand the utility of KidneyIntelX
Renalytix Plc (RENX:LON) | 27.5 -0.4 (-5.2%) | Mkt Cap: 34.7m
- Published:
30 Jun 2020 -
Author:
Edward Thomason -
Pages:
4
The announcement announced today highlights the potential breadth of the KidneyIntelX platform, opening up new routes to expand data inputs and test utility, and create opportunities alongside pharmacological therapy as a companion diagnostic. The first agreement with the University of Michigan adds an additional 800 chronic kidney disease (CKD) patients (adding to Mount Sinai’s 1,500 patients and the University of Groningen’s 3,500 patients) to analysis the performance of KidneyI